2022
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administration
2021
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.Peer-Reviewed Original ResearchInternational Prognostic IndexDA-EPOCHOverall survivalComplete responseB-cell lymphomaWorld Health OrganizationSpeakers bureauADC therapeuticsLactate dehydrogenaseCommon first-line regimensHigh serum lactate dehydrogenaseAdvisory board membersChimeric antigen receptor T cellsCentral nervous system involvementAntigen receptor T cellsGrade B-cell lymphomaAdvisory CommitteeAggressive B-cell lymphomasMYC extra copiesPoor performance statusOutcomes of patientsDe novo tumorsFirst-line regimensNervous system involvementGerminal center B-cell phenotypeGamma–Delta T‐cell Lymphomas
Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaHepatosplenic T-cell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaFive-year overall survivalCentral nervous system prophylaxisGamma delta T cellsWorld Health Organization classificationAggressive T-cell lymphomaExtensive skin ulcerationsCurative stem cell transplantationChronic antigenic stimulationStem cell transplantationInnate immune systemMost chemotherapeutic agentsSystemic methotrexateSystem prophylaxisMedian survivalMost patientsOverall prognosisOverall survivalClinical featuresOrganization classificationRisk factors
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma